Clinical data | |
---|---|
Trade names | Accupril, others |
Other names | Quinapril hydrochloride (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a692026 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 97% |
Elimination half-life | 2 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H30N2O5 |
Molar mass | 438.524 g·mol−1 |
3D model (JSmol) | |
Melting point | 120 to 130 °C (248 to 266 °F) |
| |
| |
(verify) |
Quinapril, sold under the brand name Accupril[2] by the Pfizer corporation. It a medication used to treat high blood pressure (hypertension), heart failure, and diabetic kidney disease.[1][3] It is a first line treatment for high blood pressure.[3] It is taken by mouth.[1][3]
Common side effects include headaches, dizziness, feeling tired, and cough.[3] Serious side effects may include liver problems, low blood pressure, angioedema, kidney problems, and high blood potassium.[3] Use in pregnancy and breastfeeding is not recommended.[4] It is among a class of drugs called ACE inhibitors and works by decreasing renin-angiotensin-aldosterone system activity.[3]
Quinapril was patented in 1980 and came into medical use in 1989.[5] It is available as a generic medication.[6] In 2020, it was the 253rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]